drugset / Trial / NCT02197520

A Study To Compare the Effects of Insulin Peglispro and Glargine on Insulin Sensitivity and Meal Time Insulin Requirements in Type 2 Diabetics

NCT02197520

Phase 1 Completed 24 enrolled Eli Lilly and Company
RandomizedCrossoverOpen-labelBasic science

Summary

This study will look into insulin sensitivity (how the body responds to insulin) and effects of meals on type 2 diabetics comparing insulin peglispro to insulin glargine. The study has two treatment periods, each of which will last about four weeks. One drug (insulin peglispro or insulin glargine) will be administered in each period. Participants will receive both drugs during the study. Participants may remain on stable dose metformin, as prescribed by their personal physician.

Timeline

Start
2014-07
Primary completion
2015-06
Completion
2015-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Insulin Lispro Protein / enzyme biologic Subcutaneous
Subject Insulin Peglispro Protein / enzyme biologic Subcutaneous
Comparator insulin glargine Protein / enzyme biologic Subcutaneous